Saturday 17 October 2026
Export IPHA’s income statement to Excel — free account
Innate Pharma S.A. Sponsored ADR
IPHA Healthcare Biotechnology
Innate Pharma S.A. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million, down 53.2% from fiscal 2024.
1.43
0.05
−3.38%
Follow IPHA
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | 0.00% |
+8 more TTM periods Free account |
|
| 0.00% | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(127.75) | (100.21) | (75.82) | (53.21) | |
Capital Expenditures |
(0.75) | (0.95) | (1.01) | (1.28) | |
| Other line items | |||||
Cash ROIC |
1,168.08% | (251.77%) | (72.44%) | (40.78%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | — | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
1.24 | 0.00 | 1.72 | 0.00 | |
Capex/Depreciation |
(0.14) | (0.17) | (0.10) | (0.10) | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates